With unmatched executional momentum and differentiated programs, Candid Therapeutics is defining a new future in immunology through its commitment to TCEs in autoimmune diseases. Additional trial ...

SAN DIEGO, CA, USA I June 20, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo ...

BOSTON, MA, USA & CAMBRIDGE, UK I June 19, 2025 I Cycle Pharmaceuticals announced that the FDA has approved HARLIKU (nitisinone) Tablets for the reduction ...

In-vitro lab results confirmed that the Company’s cell targeting nanoparticles successfully entered cancer cells and avoided non-cancerous cells ...